A study with sofosbuvir and ribavirin in patients co-infected with HIV and HCV

Registry ID

EUCTR2012-004154-28

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Gilead Sciences Inc

Start date

2013-02-15

Completion date

2014-07-10

Last update

2026-08-16

Conditions

• Hepatitis C Virus Infection

Summary

The primary objectives of this study are: • To determine the efficacy of treatment with SOF + RBV as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR12) • To evaluate the safety and tolerability of SOF + RBV as assessed by review of the accumulated safety data, including HIV-RNA and CD4 T-cell percent

Locations

• , , Germany
• , , Italy
• , , Spain
• , , UK

Related clinical trials

• Hepatitis C Tracker Study
• Early Detection of HCV in Injection Drug Users
• Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development

View on source registry